Cmax (pharmacology)
the peak concentration that a drug achieves in a given test area of the body
Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and before the administration of a second dose. It is a standard measurement in pharmacokinetics.
Description
Cmax is the opposite of Cmin, which is the minimum (or trough) concentration that a drug achieves after dosing. The related pharmacokinetic parameter tmax is the time at which the Cmax is observed.
After an intravenous administration, Cmax and tmax are closely dependent on the experimental protocol, since the concentrations are always decreasing after the dose. But after oral administration, Cmax and tmax are dependent on the extent, and the rate of drug absorption and the disposition profile of the drug. They could be used to characterize the properties of different formulations in the same subject.
Short term drug side effects are most likely to occur at or near the Cmax, whereas the therapeutic effect of drug with sustained duration of action usually occurs at concentrations slightly above the Cmin.
The Cmax is often measured in an effort to show bioequivalence (BE) between a generic and innovator drug product. According to the FDA, drug quality bioavailability (BA) and BE rely on pharmacokinetic measurements such as AUC and Cmax that are reflective of systemic exposure.
Begin with the source’s own compact description: “Cmax (pharmacology)” is the peak concentration that a drug achieves in a given test area of the body. The dossier treats that line as a proposition to test through Cmax, pharmacology and peak, not as a finished interpretation.
Why this record matters
The phrase “the peak concentration that a drug achieves in a given test area of the body” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Nov 19, 2025. The linked authority identifier is Q5137311. None of the 0 selected statements returned an explicit reference.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Cmax (pharmacology)”, its source revision and the description used here.
- Expand the search: follow Cmax (pharmacology) primary sources, Cmax (pharmacology) archive and Cmax research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Cmax (pharmacology)”?
- Which institution is responsible for the underlying evidence?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Cmax (pharmacology)” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.